Terms: = Endocrine gland cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Clinical Outcome
66 results:
1. Relevance of mutations in protein deubiquitinases genes and
Pękul M; Szczepaniak M; Kober P; Rusetska N; Mossakowska BJ; Baluszek S; Kowalik A; Maksymowicz M; Zieliński G; Kunicki J; Witek P; Bujko M
Front Endocrinol (Lausanne); 2024; 15():1302667. PubMed ID: 38487343
[TBL] [Abstract] [Full Text] [Related]
2. Presumed Pathogenic Germ Line and Somatic Variants in African American Thyroid cancer.
Hurst ZA; Liyanarachchi S; Brock P; He H; Nabhan F; Veloski C; Toland AE; Ringel MD; Jhiang SM
Thyroid; 2024 Mar; 34(3):378-387. PubMed ID: 38062767
[No Abstract] [Full Text] [Related]
3. braf
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract] [Full Text] [Related]
4. Role of gene sequencing in classifying struma ovarii: braf p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
[TBL] [Abstract] [Full Text] [Related]
5. braf V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.
Bandoh N; Goto T; Kato Y; Kubota A; Sakaue S; Takeda R; Hayashi S; Hayashi M; Baba S; Yamaguchi-Isochi T; Nishihara H; Kamada H
Asian J Surg; 2024 Jan; 47(1):413-419. PubMed ID: 37752023
[TBL] [Abstract] [Full Text] [Related]
6. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract] [Full Text] [Related]
7. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
Thomson JP; Hollis RL; van Baal J; Ilenkovan N; Churchman M; van de Vijver K; Dijk F; Meynert AM; Bartos C; Rye T; Croy I; Diana P; van Gent M; Creedon H; Nirsimloo R; Nussey F; Lok C; Herrington CS; Gourley C
Gynecol Oncol; 2023 Jul; 174():157-166. PubMed ID: 37207500
[TBL] [Abstract] [Full Text] [Related]
8. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
Staubitz JI; Müller C; Heymans A; Merten C; Roos B; Poplawski A; Ludt A; Strobl S; Springer E; Schad A; Roth W; Musholt TJ; Hartmann N
BJS Open; 2023 May; 7(3):. PubMed ID: 37146205
[TBL] [Abstract] [Full Text] [Related]
9. brafV600E and braf-WT Specific Antitumor Immunity in Papillary Thyroid cancer.
Ehlers M; Schmidt M; Mattes-Gyorgy K; Antke C; Enczmann J; Schlensog M; Japp A; Haase M; Allelein S; Dringenberg T; Giesel F; Esposito I; Schott M
Horm Metab Res; 2022 Dec; 54(12):852-858. PubMed ID: 36427494
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of factors influencing the clinical outcome after surgery and
Li Y; Rao M; Zheng C; Huang J; Fang D; Xiong Y; Yuan G
Front Endocrinol (Lausanne); 2022; 13():1015798. PubMed ID: 36313750
[TBL] [Abstract] [Full Text] [Related]
11. Genetic and epigenetic characterization of posterior pituitary tumors.
Schmid S; Solomon DA; Perez E; Thieme A; Kleinschmidt-DeMasters BK; Giannini C; Reinhardt A; Asa SL; Mete O; Stichel D; Siewert C; Dittmayer C; Hasselblatt M; Paulus W; Nagel C; Harter PN; Schittenhelm J; Honegger J; Rushing E; Coras R; Pfister SM; Buslei R; Koch A; Perry A; Jones DTW; von Deimling A; Capper D; Lopes MB
Acta Neuropathol; 2021 Dec; 142(6):1025-1043. PubMed ID: 34661724
[TBL] [Abstract] [Full Text] [Related]
12. Skull Base Tumors: Neuropathology and clinical Implications.
Bi WL; Santagata S
Neurosurgery; 2022 Mar; 90(3):243-261. PubMed ID: 34164689
[TBL] [Abstract] [Full Text] [Related]
13. The role of the size in thyroid cancer risk stratification.
Vianello F; Censi S; Watutantrige-Fernando S; Barollo S; Zhu YH; Albiger N; Bertazza L; Manso J; Carducci S; Benna C; Iacobone M; Galuppini F; Pennelli G; Mian C
Sci Rep; 2021 Mar; 11(1):7303. PubMed ID: 33790328
[TBL] [Abstract] [Full Text] [Related]
14. Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer.
Crezee T; Tesselaar MH; Nagarajah J; Corver WE; Morreau J; Pritchard C; Kimura S; Kuiper JG; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
Cell Oncol (Dordr); 2021 Jun; 44(3):611-625. PubMed ID: 33534128
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of
van Ipenburg JA; Naus NC; Dubbink HJ; van Ginderdeuren R; Missotten GS; Paridaens D; Verdijk RM
Br J Ophthalmol; 2021 Oct; 105(10):1454-1461. PubMed ID: 33127831
[TBL] [Abstract] [Full Text] [Related]
16. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract] [Full Text] [Related]
17. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma.
Samà MT; Grosso E; Mele C; Laurora S; Monzeglio O; Marzullo P; Boldorini R; Aluffi Valletti P; Aimaretti G; Scatolini M; Pagano L
Endocrine; 2021 Jan; 71(1):149-157. PubMed ID: 32621051
[TBL] [Abstract] [Full Text] [Related]
18. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid cancer Cell Line.
Hegedűs L; Rittler D; Garay T; Stockhammer P; Kovács I; Döme B; Theurer S; Hager T; Herold T; Kalbourtzis S; Bankfalvi A; Schmid KW; Führer D; Aigner C; Hegedűs B
Pathol Oncol Res; 2020 Oct; 26(4):2523-2535. PubMed ID: 32591993
[TBL] [Abstract] [Full Text] [Related]
19. Histopathologic Features and clinical outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component.
Wong KS; Lorch JH; Alexander EK; Marqusee E; Cho NL; Nehs MA; Doherty GM; Barletta JA
Endocr Pathol; 2020 Sep; 31(3):283-290. PubMed ID: 32445173
[TBL] [Abstract] [Full Text] [Related]
20. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
[TBL] [Abstract] [Full Text] [Related]
[Next]
